Literature DB >> 8841154

Pharmacokinetics of morphine and its glucuronides after intravenous infusion of morphine and morphine-6-glucuronide in healthy volunteers.

J Lötsch1, A Stockmann, G Kobal, K Brune, R Waibel, N Schmidt, G Geisslinger.   

Abstract

Steady-state pharmacokinetics of morphine and morphine-6-glucuronide (M-6-G) after intravenous administration of either morphine or M-6-G were determined in healthy volunteers. With a dosing regimen calculated on the basis of data obtained in a first series of experiments in four subjects (morphine: intravenous loading dose of 0.24 mg/kg for 5 minutes and an intravenous infusion of 0.069 mg.kg-1.hr-1 for 4 hours; M-6-G: loading dose of 0.011 mg/kg for 5 minutes and an infusion of 0.006 mg.kg-1.hr-1 for 4 hours), it was possible to yield plasma concentrations of morphine and M-6-G in another four subjects close to predefined targeted levels (35 and 45.5 ng/ml morphine and M-6-G, respectively). This dosing regimen may be used in further pharmacodynamic studies to compare the analgesic effects of morphine and M-6-G. In addition, metabolite kinetics of M-6-G were calculated as a function of time with use of a linear systems approach to the estimation of rate and fraction of morphine glucuronidation to M-6-G.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8841154     DOI: 10.1016/S0009-9236(96)90058-2

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

1.  ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children.

Authors:  Raja Venkatasubramanian; Tsuyoshi Fukuda; Jing Niu; Tomoyuki Mizuno; Vidya Chidambaran; Alexander A Vinks; Senthilkumar Sadhasivam
Journal:  Pharmacogenomics       Date:  2014-07       Impact factor: 2.533

Review 2.  Role of active metabolites in the use of opioids.

Authors:  Janet K Coller; Lona L Christrup; Andrew A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

Review 3.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

Review 4.  Pharmacokinetic and pharmacodynamic drug interactions with ethanol (alcohol).

Authors:  Lingtak-Neander Chan; Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

5.  Midazolam Dose Optimization in Critically Ill Pediatric Patients With Acute Respiratory Failure: A Population Pharmacokinetic-Pharmacogenomic Study.

Authors:  Athena F Zuppa; Daniela J Conrado; Nicole R Zane; Martha A Q Curley; Jonathan Bradfield; Hakon Hakonarson; Madeleine S Gastonguay; Ganesh Moorthy; Janice Prodell; Marc R Gastonguay
Journal:  Crit Care Med       Date:  2019-04       Impact factor: 7.598

6.  Elucidation of mu-Opioid Gene Structure: How Genetics Can Help Predict Responses to Opioids.

Authors:  Luda Diatchenko; J Elliott Robinson; William Maixner
Journal:  Eur J Pain Suppl       Date:  2011-11-11

7.  Dual modulation of the T-cell receptor-activated signal transduction pathway by morphine in human T lymphocytes.

Authors:  Toshiyuki Mizota; Hiroshi Tsujikawa; Takehiro Shoda; Kazuhiko Fukuda
Journal:  J Anesth       Date:  2012-08-30       Impact factor: 2.078

8.  Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine.

Authors:  J Drewe; H A Ball; C Beglinger; B Peng; A Kemmler; H Schächinger; W E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2000-09       Impact factor: 4.335

Review 9.  Morphine-6-glucuronide: an analgesic of the future?

Authors:  J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

10.  Pharmacokinetics of morphine-6-glucuronide following oral administration in healthy volunteers.

Authors:  Hanne H Villesen; Kim Kristensen; Steen H Hansen; Niels-Henrik Jensen; Ulrik Skram; Lona L Christrup
Journal:  Eur J Clin Pharmacol       Date:  2007-05-31       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.